BIIB vs REGN
Biogen and Regeneron Pharmaceuticals, side by side.
Prices and company dataas of yesterday's close
- BIIBBuy more27%
Biogen's report on Oct 28 beat profit forecasts by 27%, and analysts expect profit to grow 30% next year.
- REGNBuy more34%
Regeneron Pharmaceuticals' report on Oct 30 beat profit forecasts by 34%, and its sales grew 19% over the past year.
Percent return
- BIIB+58.81%
- REGN+42.96%
Nov 11, 2025 to Nov 11, 2026
Where they differ
- Company size: BIIB $30.0B, REGN $70.8B.
- Sales growth, 1 yr: BIIB +2.3%, REGN +19%. REGN is ahead.
- Price for $1 of next year's profit: BIIB $17, REGN $11. REGN is ahead.
- Profit per $1 of sales: BIIB 24¢, REGN 30¢. REGN is ahead.
- Cash minus debt: BIIB −$6.50B, REGN +$16.2B. REGN is ahead.
- Price change, 1 yr: BIIB +59%, REGN +43%. BIIB is ahead. S&P 500 +12%.
- How much the price swings: BIIB 35%, REGN 37%. BIIB is ahead.
| Measure | BIIBBiogen | REGNRegeneron Pharmaceuticals |
|---|---|---|
| Price and returns | ||
| Price | $253.49 | $959.69 |
| Today | +0.09% | Best in this row: +4.76% |
| 1 month | +12.27% | Best in this row: +28.51% |
| 3 months | Best in this row: +24.33% | +20.55% |
| This year | Best in this row: +43.99% | +24.78% |
| 1 year | Best in this row: +58.81% | +42.96% |
| 5 years | −4.94% | Best in this row: +54.55% |
| From 52-week high | −0.5% | −1.4% |
| How much it swings (90 days) | Best in this row: 35% | 37% |
| Valuation | ||
| Market value | $30.0B | $70.8B |
| Price vs last year's earnings | 21.9× | Best in this row: 16.5× |
| Price vs next year's expected earnings | 16.9× | Best in this row: 11.3× |
| Price vs earnings, adjusted for growth | 2.12× | Best in this row: 1.05× |
| Price to sales | Best in this row: 3.6× | 5.4× |
| Price vs cash it brings in | Best in this row: 17.7× | 23.7× |
| Company value vs operating profit | Best in this row: 13.1× | 13.2× |
| Growth | ||
| Revenue growth, 1 year | +2.3% | Best in this row: +18.6% |
| Revenue growth a year, last 3 years | −0.9% | Best in this row: +5.6% |
| Earnings per share growth, last year | −7.9% | Best in this row: +1.9% |
| Earnings per share growth expected next year | Best in this row: +29.9% | +4.1% |
| Profitability | ||
| Kept from sales after making the product | Best in this row: 75.8% | 46.7% |
| Kept as operating profit | 23.5% | Best in this row: 30.4% |
| Kept as final profit | 3.4% | Best in this row: 28.5% |
| Kept as spare cash | 20.1% | Best in this row: 22.6% |
| Profit on shareholders' money | 1.9% | Best in this row: 14.9% |
| Profit on all money put in | 7.4% | Best in this row: 16.3% |
| Balance sheet | ||
| Net cash (cash minus debt) | −$6.50B | Best in this row: $16.2B |
| Debt for each $1 of shareholders' money | 0.41× | Best in this row: 0.08× |
| Short-term assets per $1 of bills due | 1.95× | Best in this row: 3.35× |
| Dividend yield | – | 0.42% |
| Share of profit paid as dividends | – | 8% |
| Our readPro | ||
| Our call | Buy more | Buy more |
| Why | Biogen's report on Oct 28 beat profit forecasts by 27%, and analysts expect profit to grow 30% next year. | Regeneron Pharmaceuticals' report on Oct 30 beat profit forecasts by 34%, and its sales grew 19% over the past year. |
| Where the price sits | in the full report | in the full report |
| Our overall score (out of 100) | 60 | Best in this row: 64 |
| Our value score | 70 | Best in this row: 97 |
| Our growth score | Best in this row: 40 | 39 |
| Our quality score | 70 | Best in this row: 80 |
| Our price trend score | Best in this row: 70 | 62 |
| Earnings and analysts | ||
| Analyst consensus | Buy | Buy |
| To average analyst target | Best in this row: +4.9% | −0.2% |
| Average analyst target | $266.00 | $958.17 |
| Analysts rating it a buy | Best in this row: 69% | 68% |
| Buy ratings added, 3 months | Best in this row: +2 | +1 |
| Analysts covering | 25 | 24 |
REGN: faster growth at a lower P/E
Our pick of these: Regeneron Pharmaceuticals
Sales growth +18.6% vs +2.3%
BIIB +2.3%, REGN +18.6%.Forward P/E per point of sales growth 0.61 vs 7.33
BIIB 7.33, REGN 0.61.Keeps 30.4% of sales as operating profit, vs 23.5%
BIIB 23.5%, REGN 30.4%.Where it loses: BIIB has more analyst upside, +4.9% vs −0.2%
Cover this stock to see the full report
The call, its reasons and what would change it are free for everyone. The price zones, the whole brief and how the call has moved come with covering a stock. Use one of your three covered slots, or go Pro for every stock.
Prices as of yesterday, 3:59 PM ET. A view, not advice.